m+Medelevator.RU
← Поиск публикаций
Frontiers in medicine · 2026

Bedside bronchoscopy in intubated patients with acute exacerbation of COPD requiring invasive mechanical ventilation: clinical applications, procedural timing, and standardized management.

СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

He Juan, Yao Yu, Chen Xing, Yang Yanyan, Tao Wen

Аннотация

INTRODUCTION: Bedside bronchoscopy is a valuable diagnostic and therapeutic tool for intubated patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) receiving invasive mechanical ventilation, yet evidence-based guidance on procedural timing remains limited.

METHODS: This narrative review synthesized evidence from guidelines, systematic reviews, randomized controlled trials, and clinical studies identified through PubMed, Cochrane Library, and Chinese databases (CNKI, Wanfang) from inception through June 2026. Selection was iterative and based on relevance to the four clinical scenarios examined.

RESULTS: The available evidence suggests that bedside bronchoscopy may be associated with improved oxygenation, reduced ventilator days, lower VAP rates, and facilitated weaning. We propose a preliminary four-scenario framework for procedural timing: early post-intubation, during mechanical ventilation, pre-extubation (at the proposed pulmonary infection control window), and post-extubation failure. Key aspects of standardized management-including pre-procedural risk assessment, ventilator adjustments, sedation strategies, intraprocedural monitoring, and post-procedural care-are discussed, with special attention to resource constraints in secondary hospital ICUs.

DISCUSSION: The evidence base remains limited and predominantly derived from small, single-center studies, many with potential risk of bias. This framework is hypothesis-generating and requires prospective validation before informing clinical practice recommendations. Future pragmatic multicenter randomized trials are needed.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты